Can oral terbinafine be used concomitantly with statins (HMG-CoA reductase inhibitors)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 1, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Can Oral Terbinafine Be Used Concomitantly with Statins?

Yes, oral terbinafine can be safely used at the same time as statins, as terbinafine does not significantly inhibit CYP3A4 (the enzyme that metabolizes most statins) and has minimal drug-drug interactions with this class of medications. 1

Mechanism and Safety Profile

Terbinafine primarily affects the cytochrome P450 2D6 isoenzyme, not the CYP3A4 enzyme that metabolizes simvastatin, lovastatin, and atorvastatin 1. This fundamental difference in metabolic pathways means terbinafine does not increase statin blood levels or the risk of statin-associated myopathy through pharmacokinetic interactions.

The American Heart Association explicitly recommends that statin therapy can be continued when taking terbinafine 1. This stands in stark contrast to azole antifungals (itraconazole, ketoconazole, posaconazole), which are potent CYP3A4 inhibitors and can increase statin exposure by 10-fold or more, leading to rhabdomyolysis 2, 3.

Clinical Monitoring Recommendations

While the combination is safe, standard statin monitoring should continue 1:

  • Baseline assessment: Evaluate muscle symptoms and obtain CK levels before starting therapy 4, 1
  • Ongoing monitoring: Check for headache, dyspepsia, muscle soreness, tenderness, or pain at 6-8 weeks after starting therapy, then at each follow-up visit 4, 1
  • Liver function: Obtain ALT/AST initially, after 12 weeks, then annually 1

High-Risk Patients Requiring Enhanced Vigilance

Certain patients warrant more careful monitoring regardless of concurrent medications 4, 1:

  • Advanced age (especially >80 years), particularly frail elderly women
  • Small body frame and frailty
  • Multisystem disease (chronic renal insufficiency, especially from diabetes)
  • Multiple medications
  • Perioperative periods

Practical Clinical Algorithm

Step 1: Confirm the patient needs both medications

  • Terbinafine is indicated for dermatophyte onychomycosis or tinea infections 5
  • Statin is indicated for cardiovascular risk reduction

Step 2: Continue both medications without dose adjustment

  • No statin dose reduction is required when adding terbinafine 1
  • No terbinafine dose adjustment is required in patients on statins

Step 3: Apply standard statin monitoring protocols

  • Do not implement additional monitoring beyond routine statin surveillance 1
  • Instruct patients to report muscle pain, weakness, or dark urine immediately 4

Step 4: Consider renal function for terbinafine dosing

  • Terbinafine is contraindicated in patients with creatinine clearance ≤50 mL/min 6
  • If CrCl ≤50 mL/min, use topical antifungals (amorolfine or ciclopirox) instead 6

Key Contrast with Other Antifungals

This favorable interaction profile distinguishes terbinafine from azole antifungals 2, 3:

  • Itraconazole/ketoconazole: Contraindicated with simvastatin and lovastatin; can increase atorvastatin exposure significantly 2, 3, 7
  • Terbinafine: Safe with all statins; recommended as the preferred antifungal when systemic therapy is needed in statin users 2

When a patient on CYP3A4-metabolized statins requires antifungal treatment, the recommended approach is: (1) use topical antifungal if possible, (2) switch to terbinafine for systemic therapy, or (3) temporarily discontinue the statin 2.

Common Pitfalls to Avoid

  • Do not confuse terbinafine with azole antifungals: Terbinafine is safe with statins; azoles are not 2, 3
  • Do not implement unnecessary monitoring: Standard statin monitoring is sufficient; no additional testing is required for the combination 1
  • Do not overlook renal function: Terbinafine itself is contraindicated in significant renal impairment (CrCl ≤50 mL/min), independent of statin use 6
  • Do not use terbinafine in decompensated cirrhosis: While statins are safe in compensated cirrhosis from NAFLD, both medications should be used cautiously in decompensated liver disease 8

References

Guideline

Statin Therapy and Terbinafine Interaction

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Terbinafine Safety Profile

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Statin Therapy in Fatty Liver Disease

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.